Halozyme Therapeutics (HALO) Intangibles (2022 - 2026)

Halozyme Therapeutics (HALO) has 5 years of Intangibles data on file, last reported at $952.0 million in Q1 2026.

• On a quarterly basis, Intangibles rose 147.86% year-over-year to $952.0 million in Q1 2026; TTM through Mar 2026 was $952.0 million, a 147.86% increase from a year earlier, with the FY2025 full-year figure at $981.5 million, up 144.25% from the prior year.
• Intangibles for Q1 2026 stood at $952.0 million, down from $981.5 million in the prior quarter.
• Over the last five years, Intangibles for HALO reached as high as $981.5 million in Q4 2025 and fell as low as $348.5 million in Q3 2025.
• Historically, Intangibles has averaged $576.3 million across 5 years, with a median of $481.8 million in 2023.
• Across the five-year window, Intangibles slumped 48.29% in 2023 and surged 147.86% in 2026, its largest moves.
• Year by year, Intangibles stood at $546.7 million in 2022, then slipped by 13.5% to $472.9 million in 2023, then declined by 15.02% to $401.8 million in 2024, then soared by 144.25% to $981.5 million in 2025, then fell by 3.01% to $952.0 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $952.0 million in Q1 2026, $981.5 million in Q4 2025, and $348.5 million in Q3 2025.